Ambivalent effect of immunoglobulins on the complement system: Activation versus inhibition

被引:51
作者
Basta, Milan [1 ]
机构
[1] NINDS, NIH, Bethesda, MD 20892 USA
关键词
Complement activation pathways; Immunoglobulins; Complement fragments; Scavenging; High-dose intravenous immunoglobulins (IVIG);
D O I
10.1016/j.molimm.2008.07.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pathogen and self-specific antibodies are known for their ability to trigger generation of active complement fragments that then serve as effectors of cell damage. The remainder of the immunoglobulin pool of the host has the capacity to quench harmful effects of activated complement cascade by preventing active complement fragments from binding to their specific receptors. This scavenging function is mediated by different acceptor sites within the immunoglobulin molecule. Large fragments, such as C3b and C4b are preferentially bound to the Fc region, while biologically potent C3a and C5a anaphylatoxins get neutralized by low-affinity interaction with the constant domain of the F(ab)'(2). The ambivalent effect of immunoglobulins on the complement system implies their role in homeostasis as well as expansion of use of high-dose intravenous immunoglobulins in diseases and states mediated by inappropriate complement activation. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4073 / 4079
页数:7
相关论文
共 43 条
[31]   PROTEINS SEPARATED FROM HUMAN-IGG MOLECULES [J].
NEZLIN, R ;
FREYWALD, A ;
OPPERMANN, M .
MOLECULAR IMMUNOLOGY, 1993, 30 (10) :935-940
[32]   IGG INHIBITS THE INCREASE OF PLATELET-ASSOCIATED C(3) STIMULATED BY ANTIPLATETLET ANTIBODIES [J].
NOMURA, S ;
MIYAZAKI, Y ;
MIYAKE, T ;
YAMAGUCHI, K ;
KIDO, H ;
KAWAKATSU, T ;
FUKUROI, T ;
KAGAWA, H ;
SUZUKI, M ;
YANABU, M ;
KOKAWA, T .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1993, 93 (03) :452-455
[33]  
REID KBM, 1998, HUMAN COMPLEMENT SYS, P41
[34]   Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation [J].
Rieben, R ;
Roos, A ;
Muizert, Y ;
Tinguely, C ;
Gerritsen, AF ;
Daha, MR .
BLOOD, 1999, 93 (03) :942-951
[35]   IgM-enriched human intravenous immunoglobulin strongly inhibits complement-dependent porcine cell cytotoxicity mediated by human xenoreactive antibodies [J].
Roos, A ;
Rieben, R ;
Faber-Krol, MC ;
Daha, MR .
XENOTRANSPLANTATION, 2003, 10 (06) :596-605
[36]   HIGH-DOSE IMMUNOGLOBULIN THERAPY FOR SEVERE IGA NEPHROPATHY AND HENOCH-SCHONLEIN PURPURA [J].
ROSTOKER, G ;
DESVAUXBELGHITI, D ;
PILATTE, Y ;
PETITPHAR, M ;
PHILIPPON, C ;
DEFORGES, L ;
TERZIDIS, H ;
INTRATOR, L ;
ANDRE, C ;
ADNOT, S ;
BONIN, P ;
BIERLING, P ;
REMY, P ;
LAGRUE, G ;
LANG, P ;
WEIL, B .
ANNALS OF INTERNAL MEDICINE, 1994, 120 (06) :476-484
[37]   Complement activation during hemorrhagic shock and resuscitation in swine [J].
Szebeni, J ;
Baranyi, L ;
Savay, S ;
Götze, O ;
Alving, CR ;
Bünger, R ;
Mongan, PD .
SHOCK, 2003, 20 (04) :347-355
[38]  
Szebeni J, 2004, COMPLEMENT SYSTEM: NOVEL ROLES IN HEALTH AND DISEASE, P361, DOI 10.1007/1-4020-8056-5_17
[39]  
Takahashi M, 2007, ADV EXP MED BIOL, V598, P93
[40]  
WALPEN AJ, 2007, J IMMUNOL, V179, P4101